Announced
Completed
Synopsis
Agilent, an American analytical instrumentation development and manufacturing company, completed the acquisition of Resolution Bioscience, a cancer diagnostics solutions provider, for $695m. "The Resolution Bioscience team and powerful technology are strategic and important additions to Agilent’s growing business in precision oncology solutions. This also accelerates our work to more broadly deliver precision oncology testing for patients worldwide with NGS-based diagnostic kits. We’re excited to have Resolution Bioscience joining with us to expand our work in the fight against cancer," Mike McMullen, Agilent President and CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.